LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Listă Acțiuni・Amgen Inc

Amgen Inc

Închisă

SectorSănătate

326.2 -3.03

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

325.13

Maxim

336.3

Indicatori cheie
By Trading Economics
Venit	486M 1.8B
Vânzări	-1.3B 8.6B
P/E Medie Sector	22.936 51.415
EPS	5.15
Randament dividend	2.91
Marjă de profit	21.107
Angajați	31,500
EBITDA	-2.3B 2.7B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+8.47% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	2.91% 2.34%
Următoarele câștiguri	4 aug. 2026
Data viitoare de dividende	5 iun. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-5.4B 178B
Deschiderea anterioară	329.23
Închiderea anterioară	326.2

Sentimentul știrilor

By Acuity

32%

68%

81 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

270.44 / 276.44 Suport & Rezistență

Amgen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

30 apr. 2026, 20:16 UTC

Câștiguri

Amgen Posts Higher 1Q Profit, Revenue

6 apr. 2026, 17:09 UTC

Principalele dinamici ale pieței

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

3 feb. 2026, 21:49 UTC

Câștiguri

Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

6 ian. 2026, 15:14 UTC

Achiziții, Fuziuni, Preluări

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

19 nov. 2025, 21:55 UTC

Principalele dinamici ale pieței

Amgen Lung Cancer Drug Gets Full Approval From FDA

30 apr. 2026, 20:01 UTC

Câștiguri

Amgen Sees FY26 EPS $15.62-EPS $17.10 >AMGN

30 apr. 2026, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Prolia Sales $727M >AMGN

30 apr. 2026, 20:01 UTC

Câștiguri

Amgen Sees FY26 Rev $37.1B-$38.5B >AMGN

30 apr. 2026, 20:01 UTC

Câștiguri

Amgen Sees FY26 Adj EPS $21.70-Adj EPS $23.10 >AMGN

30 apr. 2026, 20:01 UTC

Câștiguri

Amgen 1Q Adj EPS $5.15 >AMGN

30 apr. 2026, 20:01 UTC

Câștiguri

Amgen 1Q Rev $8.62B >AMGN

30 apr. 2026, 20:01 UTC

Câștiguri

Amgen 1Q Net $1.82B >AMGN

30 apr. 2026, 20:01 UTC

Câștiguri

Amgen 1Q EPS $3.34 >AMGN

1 apr. 2026, 20:07 UTC

Achiziții, Fuziuni, Preluări

Why 2026 Is Biotech's Comeback Year -- Barrons.com

4 feb. 2026, 19:56 UTC

Market Talk

Amgen's Strong Core Growth Offsets Wait for Weightloss Drug -- Market Talk

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide XGEVA Sales $447M >AMGN

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide Enbrel Sales $532M >AMGN

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen 4Q Adj EPS $5.29 >AMGN

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen 4Q Net $1.33B >AMGN

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide Prolia Sales $1.05B >AMGN

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen 4Q Rev $9.9B >AMGN

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen Sees FY Adj EPS $21.60-Adj EPS $23.00 >AMGN

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide Neulasta Sales $132M >AMGN

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen Sees FY Rev $37B-$38.4B >AMGN

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen Sees FY EPS $15.45-EPS $16.94 >AMGN

3 feb. 2026, 21:01 UTC

Câștiguri

Amgen 4Q EPS $2.45 >AMGN

28 ian. 2026, 17:47 UTC

Câștiguri

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

6 ian. 2026, 14:01 UTC

Achiziții, Fuziuni, Preluări

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

6 ian. 2026, 14:01 UTC

Achiziții, Fuziuni, Preluări

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

6 ian. 2026, 14:00 UTC

Achiziții, Fuziuni, Preluări

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

Comparație

Modificare preț

Amgen Inc Așteptări

Obiectiv de preț

By TipRanks

8.47% sus

Prognoză pe 12 luni

Medie 364.7 USD 8.47%

Maxim 427 USD

Minim 300 USD

În baza a 24 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAmgen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

24 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 24 analiști care au acordat evaluări ale acțiunilor Amgen Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

270.44 / 276.44Suport & Rezistență

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

81 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.